Upon the review and approval of the plenary meeting of 11th Pharmacopoeia Commission Executive Committee, China’s National Medical Products Administration (NMPA) and National Healthcare Commission (NHC) have jointly released the “Pharmacopoeia of the People’s Republic of China” (hereinafter referred to as “Chinese Pharmacopoeia”) .
The Chinese Pharmacopoeia will be implemented from 30 December 2020 onwards. The list separated into four segments involves 5,911 varieties with 319 newly added items, 3,177 revised, 10 removed, and 4 adjusted items.
Further information pertaining can be obtained from our previous news on the draft CP:
Chinese Pharmacopoeia 2020 draft approved by the Chinese Pharmacopoeia Commission